Study details: Oral chemotherapy with MLN0415
Purpose of Study: This study involves the use of a new oral chemotherapy agent (MLN0415) for the treatment of canine lymphomas. MLN0415 inhibits a protein known as IKK; this protein is known to contribute to cancer progression and drug resistance in human lymphomas, and the same is suspected in canine lymphomas. This is a pilot study to determine whether MLN0415 has activity against untreated or relapsed canine multicentric lymphomas. MLN0415 will be administered orally twice daily and dogs will be rechecked at Purdue at weekly intervals. For more information, click here.